Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V. Aredo, Heather A. Wakelee, Joel W. Neal et al.|Journal of Thoracic Oncology|2021Cited by 131
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality AssuranceMaheen Z. Abidi, Mark E. Dailey, David M. Aboulafia et al.|Cancer Cell|2020Cited by 33